Route of Administration
Dosage Form / Strength/Composition
Film-coated tablet 25 mg, 100 mg
Tablet core contains: dibasic calcium phosphate anhydrous, magnesium stearate,
microcrystalline cellulose, sodium starch glycolate
Film-coating contains: ferrosofferic oxide/Black iron oxide,
hydroxypropyl methylcellulose (HPMC) 2910/hypromellose, iron oxide red, lactose monohydrate,
macrogol/polyethylene glycol (PEG) 3350, titanium dioxide, triacetin
25 mg: 8 mm round tan immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side.
100 mg: oval (17 x 8.5 mm) lavender immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side.
Packaging: LORBRENA is supplied as follows:25 mg
*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product:
1 866 723-7111.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at